Cargando…

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment

The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyung Seok, Choi, Ji-Yeob, Lee, Mi-Jeong, Park, Seho, Yeo, Chang-Woo, Lee, Sang Seop, Shin, Jae-Gook, Park, Byeong-Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154335/ https://www.ncbi.nlm.nih.gov/pubmed/21860550 http://dx.doi.org/10.3346/jkms.2011.26.8.1007

Ejemplares similares

Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study
por: Lee, Ju-Hyun, et al.
Publicado: (2010)

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
por: Lee, Hye Ja, et al.
Publicado: (2011)

The Feasibility of Endoscopy-Assisted Breast Conservation Surgery for Patients with Early Breast Cancer
por: Park, Hyung Seok, et al.
Publicado: (2011)

The Impact of Local and Regional Recurrence on Distant Metastasis and Survival in Patients Treated with Breast Conservation Therapy
por: Lee, Jong Seok, et al.
Publicado: (2011)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Human Leukocyte Antigen-G (HLA-G) Polymorphism and Expression in Breast Cancer Patients
por: Jeong, Seri, et al.
Publicado: (2014)

Clinicopathologic Features and Outcomes of Metaplastic Breast Carcinoma: Comparison with Invasive Ductal Carcinoma of the Breast
por: Park, Hyung Seok, et al.
Publicado: (2010)

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
por: Woo, Hye In, et al.
Publicado: (2017)

Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers
por: Lee, Janghee, et al.
Publicado: (2015)

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Lee, Changro, et al.
Publicado: (2016)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade
por: Lee, Jeea, et al.
Publicado: (2022)

Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms
por: Kim, Eun-Young, et al.
Publicado: (2017)

Quasi-Irreversible Inhibition of CYP2D6 by Berberine
por: Kim, Ha Gyeong, et al.
Publicado: (2020)

How Many Sentinel Lymph Nodes Are Enough for Accurate Axillary Staging in T1-2 Breast Cancer?
por: Ban, Eun Jeong, et al.
Publicado: (2011)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
por: Lee, Joomi, et al.
Publicado: (2019)

Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Ahn, Jee Hyun, et al.
Publicado: (2021)

Time-Sequencing of the Neutrophil-to-Lymphocyte Ratio to Predict Prognosis of Triple-Negative Breast Cancer
por: Kim, Joo-Heung, et al.
Publicado: (2021)

Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
por: Zafra-Ceres, Mercedes, et al.
Publicado: (2013)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Is the frozen section examination for sentinel lymph node necessary in early breast cancer patients?
por: Yoon, Kwang Hyun, et al.
Publicado: (2019)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Clinicopathological Characteristics of Male Breast Cancer
por: Park, Seho, et al.
Publicado: (2008)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Clinicopathological Characteristics of Mucinous Carcinoma of the Breast in Korea: Comparison with Invasive Ductal Carcinoma-Not Otherwise Specified
por: Park, Seho, et al.
Publicado: (2010)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients
por: Choi, Sungim, et al.
Publicado: (2022)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
por: Wickramage, Ishani, et al.
Publicado: (2017)

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
por: Bezerra, Lucas Soares, et al.
Publicado: (2018)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
por: Lee, Suk Jun, et al.
Publicado: (2023)

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers
por: Park, Sunny, et al.
Publicado: (2017)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kkbmkmiqvnheppuknr19ku1e42